Guardant Health Inc (GH)

147.18 -2.27  -1.52% NASDAQ Feb 26, 20:00 USD
View Full Chart
Price Chart
View All GH News

News

View All Events

Events

Date Type Description
05/07/2021 Earnings Guardant Health Inc First Quarter Earnings Results for 2021
05/07/2021 Misc Guardant Health Inc First Quarter Earnings Conference Call for 2021
02/24/2021 Earnings Guardant Health Inc Fourth Quarter Earnings Result for 2020
02/24/2021 17:00 EST Misc Guardant Health Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Guardant Health Inc Third Quarter Earnings Result for 2020
11/05/2020 16:30 EST Misc Guardant Health Inc Third Quarter Earnings Conference Call for 2020
08/06/2020 16:30 EDT Misc Guardant Health Inc Second Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Guardant Health Inc Second Quarter Earnings Result for 2020
06/12/2020 09:30 PDT Misc Guardant Health Inc Annual General Meeting for 2019
05/07/2020 17:00 EDT Misc Guardant Health Inc First Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.guardanthealth.com
  • Investor Relations URL: N/A
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: May. 07, 2021
  • Last Earnings Release: Feb. 24, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Lunar-1, for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Top Fund Holders

Symbol Name Weighting
EDOC Global X Telemedicine & Digital Hlth ETF 4.81%
BBH VanEck Vectors Biotech ETF 4.57%
IHF iShares US Healthcare Providers ETF 2.36%
GTMRX Goldman Sachs Small/Mid Cap Growth R 2.11%
FXH First Trust Health Care AlphaDEX® ETF 1.80%
CHCKX AB Discovery Growth K 1.64%
FSMRX Franklin Small-Mid Cap Growth R 1.42%
LMPFX ClearBridge Aggressive Growth FI 1.29%
IBB iShares Nasdaq Biotechnology ETF 1.29%
VISGX Vanguard Small Cap Growth Index Inv 0.58%
VBK Vanguard Small-Cap Growth ETF 0.58%
NAESX Vanguard Small Cap Index Inv 0.27%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.